Clinical Trial Update: A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy [Phase 2]

View source ↗

Summary

This update notes the completion of a Phase 2 study evaluating IONIS-FB-LRx for primary IgA nephropathy, assessing its effectiveness and safety in adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• IONIS-FB-LRx (complement factor B antisense inhibitor)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Primary IgA Nephropathy | Phase 2 | Status: COMPLETED